Morphic Holding (Nasdaq:MORF) - 주가, 뉴스 및 분석

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MORF 주식 개요

모픽 홀딩은 자가 면역, 심혈관 및 대사 질환, 섬유증 및 암 치료를 위한 경구용 저분자 인테그린 치료제를 발견하고 개발하는 바이오 제약 회사입니다.

MORF 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 76.54% 증가할 것으로 예상됩니다.

위험 분석

수익은 향후 3년간 연평균 8.7% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

Morphic Holding, Inc. 경쟁사

Ambrx Biopharma

NasdaqGS:AMAM

US$1.8b

IDEAYA Biosciences

NasdaqGS:IDYA

US$2.6b

Arrowhead Pharmaceuticals

NasdaqGS:ARWR

US$2.4b

Geron

NasdaqGS:GERN

US$2.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Morphic Holding
과거 주가
현재 주가	US$56.99
52주 최고치	US$57.00
52주 최저치	US$19.35
베타	1.49
11개월 변경	1.79%
3개월 변경 사항	94.97%
1년 변경 사항	12.30%
33년 변화	1.23%
5년 변화	158.58%
IPO 이후 변화	216.61%

최근 뉴스 및 업데이트

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Nov 03

Morphic: Pioneering Integrin Medicines

Oct 13

주주 수익률

	MORF	US Biotechs	US 마켓
7D	0.2%	-2.9%	0.9%
1Y	12.3%	18.9%	32.3%

수익률 대 산업: MORF 지난 1년 동안 12.6 %를 반환한 US Biotechs 산업과 일치했습니다.

수익률 대 시장: MORF 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MORF's price volatile compared to industry and market?
MORF volatility
MORF Average Weekly Movement	22.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: MORF 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MORF 의 주간 변동성은 지난 1년 동안 15% 에서 23% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2014	128	Praveen Tipirneni	www.morphictx.com

바이오 제약 회사인 모픽 홀딩은 자가 면역, 심혈관 및 대사 질환, 섬유증 및 암 치료를 위한 경구용 저분자 인테그린 치료제를 발굴 및 개발하는 회사입니다. 주요 제품 후보인 염증에 영향을 미치는 a4ß7 특이적 인테그린 억제제인 MORF-057은 염증성 장 질환 치료를 위한 임상 2상 시험을 진행 중입니다. 이 회사가 파이프라인으로 개발 중인 제품으로는 위장관 궤양, 주머니염 등 추가적인 잠재적 위장관계 질환 적응증을 위한 차세대 a4ß7 억제제, 골수섬유증 및 고형 종양 치료를 위한 avß8, 폐고혈압을 위한 피브로넥틴 인테그린 등이 있습니다.

Morphic Holding, Inc. 기본 사항 요약

Morphic Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MORF 기본 통계
시가총액	US$2.86b
수익(TTM)	-US$179.83m
수익(TTM)	n/a

0.0x

P/S 비율

-15.9x

P/E 비율

MORF 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MORF 손익 계산서(TTM)
수익	US$0
수익 비용	US$165.93m
총 이익	-US$165.93m
기타 비용	US$13.90m
수익	-US$179.83m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.58
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

MORF 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

This company has been acquired

MORF 주식 개요

보상

위험 분석

Morphic Holding, Inc. 경쟁사

NasdaqGS:AMAM

US$1.8b

NasdaqGS:IDYA

US$2.6b

NasdaqGS:ARWR

US$2.4b

NasdaqGS:GERN

US$2.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation